American Review of Respiratory Disease · 1982 · 157 citations · 0 references
PharmacyInfectious DiseasesPharmacologyChemotherapyDrug DeliveryOral Drug DeliveryAntifungal PharmacotherapyAntifungal TherapyFungal InfectionsLiposomal FormulationsLiposome-based DeliveryParasitic InfectionsAcute Drug ToxicityAcute Tissue ToxicityLiposomal Delivery SystemsLiposomal NanocarriersLiposome Delivery SystemsLiposome Drug DeliveryLiposome ToxicityLiposomes
Incorporation of amphotericin B into liposomes significantly altered its toxicity, tissue distribution, and efficacy. Compared with intravenously administered amphotericin B-desoxycholate, liposome-amphotericin B showed a reduced acute toxicity and a maximal tolerable dose 9 times greater than amphotericin B-desoxycholate. Liposome-amphotericin B also produced higher tissue and lower serum concentrations than amphotericin B-desoxycholate, and was significantly more effective in prolonging survival of mice infected with Histoplasma capsulatum.